Company Information

Company Profile

Vallon Pharmaceuticals (NASDAQ: VLON) is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel abuse-deterrent medications for CNS disorders. The Company’s lead investigational product candidate, ADAIR (Abuse-Deterrent Amphetamine Immediate-Release), is a proprietary abuse-deterrent formulation of immediate release (IR) dextroamphetamine in development for the treatment of attention deficit hyperactivity disorder (ADHD) and narcolepsy. ADAIR is designed to deter attempts to crush and snort and provides barriers to injection. Leveraging the clinical success of dextroamphetamine, we are developing ADAIR through a streamlined 505(b)(2) U.S. FDA regulatory pathway, which is expected to obviate the need for large Phase 2 and Phase 3 efficacy and safety studies. If approved, ADAIR is expected to be the first abuse-deterrent, immediate-release formulation of dextroamphetamine.

IR Contacts

Investor & Media Relations
Jenene Thomas
(833) 475-8247

Transfer Agent
VStock Transfer LLC
(212) 828-8436

U.S. Legal Council
Thompson Hine LLP
335 Madison Ave, 12th Floor
New York, NY 10017
(212) 908-3905

111 Wood Ave S.
Iselin, NJ 08830
(732) 243-7000

Frequently Asked Questions

How is Vallon stock traded?

Vallon stock is traded on NASDAQ under the ticker symbol VLON

Can I buy stock directly from Vallon?

No, you will need to contact a licensed stockbroker or use an online trading account

How do I get my purchased shares?

Contact VStock Transfer LLP  by telephone at (212) 828-8436 or by email at

What is Vallon’s industry classification?

Sector: Pharmaceutical Preparations
SIC: 2834

Where is Vallon’s corporate headquarters?

100 N. 18th Street, Suite 300, Philadelphia, PA 19103

When was Vallon incorporated?

Vallon was incorporated in the state of Delaware on January 11, 2018 and completed its organization, formation, and initial capitalization activities effective as of June 7, 2018